Translational Genomics
Research Program
Leaders
Where we are
SJD Barcelona Children's Hospital
Related websites
SJD Barcelona Children's Hospital Our Translational Genomics group merges scientific expertise in genomics and bioinformatics (with expertise and knowledge of specific genetic alterations) and the clinical context of paediatric solid tumours. We carry out research projects focusing on the study of the different genetic and epigenetic alterations underlying the clinical-pathological behaviour of paediatric tumours in order to identify new biomarkers and therapeutic targets that would constitute advances in the treatment and clinical management of these patients.
We have been an AGAUR consolidated research group (Government of Catalonia, reference 2017 SGR 1672) since 2014.
Research lines
- The study of the functional and clinical implications of DNA methylation changes.
- The development of epigenetic markers for the molecular classification of paediatric tumours.
- The development of a digital platform for the molecular classification of paediatric tumours.
- Epigenetic approaches to the pathogenesis of neuroblastoma.
- The development of treatment response biomarkers in neuroblastoma.
Scientific objectives
- To develop and validate (epi-)genetic biomarkers to improve the diagnosis, prognosis and monitoring of diseases.
- To investigate the possibility of using (epi-)genetic biomarkers in body fluids (liquid biopsy) of patients as non-invasive molecular markers for diagnosis, disease monitoring and treatment response.
- To develop tools for the implementation of new biomarkers in clinical practice.
- To investigate the functional and clinical implications of (epi-) genetic changes involved in the clinical-pathological behaviour of developmental tumours in order to identify potential therapeutic targets.
Area/Field of expertise
Analysis of specific genetic alterations in paediatric solid tumours. Clinical expertise in order to translate molecular data into a clinical opportunity.
Experience in the field of genomics and functional bioinformatics.
Development and validation of biomarkers for patient classification, prognosis determination and response to treatment of paediatric solid tumours.
Experience in designing our own analytical tools.
Group members
-
Jefe de Grupo Senior
-
Investigador
-
Alba Parra Checa
Ayudante de investigación
-
Investigador post-doc
-
Júlia Gallego Santos
Técnico
-
Sara Garcia Palomino
-
Investigador pre-doc
Last Publications
- Salvador, L, del Valle, J, Dorca, E, Chong, AS, Chong, AL, Valenzuela, JC, Munté, E, Rioja, C, Marti-Sanchez L, Salinas, M, Darder, E, Fabian, MR, Brunet, J, Salvador-Hernandez H, Lázaro, C and Rivera, B DICER1 in pediatric and adult cancer predisposition populations: Prevalence, phenotypes, and mosaicism GENETICS IN MEDICINE . 27(5): .
- Balaguer-Lluna L, Gene-Olaciregui N, Aschero MR, Resa-Parés C, Paco-Mercader S, Cuadrado-Vilanova M, Burgeño-Sandoval V, Baulenas-Farrés M, Monterrubio C, Manzanares-Quintela A, Rodriguez E, Lavarino C, Mora J and Carcaboso AM Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas. JOURNAL OF NEURO-ONCOLOGY . 172(3): 599-611.
- Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados AP, Uriarte-Arrazola I, Mazuelas H, Blanco I, Valverde C, Carrió M, Villanueva A, De Raedt T, Romagosa C, Gel B, Salvador-Hernandez H, Ferrer M, Lázaro C and Serra E Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models CLINICAL CANCER RESEARCH . 31(5): 907-920.
Projects
- Project name:
- Multi-ómica y cribado masivo de fármacos para el tratamiento dirigido del Neuroblastoma resistente al tratamiento
- Leader
- Cinzia Emilia Lavarino , Marta García López
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI23/00120
- Starting - finishing date:
- 2024 - 2026
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Desarrollo de clasificadores epigenéticos para el Cáncer Pediátrico (ECPC)
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00519
- Starting - finishing date:
- 2021 - 2025
Theses
-
Combined therapies for neuroblastoma based on the activation of the calcium sensing receptor
- Author
- Gonçalves Alves, Eliana Carolina
- Institution
- UNIVERSIDAD DE BARCELONA
-
Developmental Tumors, Epigenetics and microRNAs.
- Author
- Gomez Gonzalez, Soledad
- Institution
- UNIVERSIDAD DE BARCELONA
-
Design and development of methods for paediatric tumours classification using DNA methylation profiles
- Author
- Llano Viles, Joshua
- Institution
- UNIVERSIDAD POLITÉCNICA DE CATALUNYA
News
-
Automated learning app improves accessibility to medulloblastoma classification
A team from the Sant Joan de Déu Research Institute, Sant Joan de Déu Hospital, and the Polytechnic University of Catalonia, has developed an artificial intelligence-based application to make the classification of medulloblastoma subgroups more accessible, less costly, and faster
-
The Catalan Tumour Bank Network launches a new corporate identity and website
The Xarxa de Bancs de Tumor de Catalunya (XBTC) has renewed its corporate identity and website to project a more dynamic and local network in the biomedicine and health ecosystem.
-
New research facilities for studying children's cancer
New facilities have been opened for the children's oncology laboratory of the Institut de Recerca Sant Joan de Déu - SJD Barcelona Children's Hospital to celebrate 20 years of research. These laboratories are unique in their exclusive dedication to pediatric tumors and have over 50 researchers who focus on the study of more than ten developmental tumors.
More activities
-
#SeminarIRSJD · Identification of gene signatures and potential therapeutic targets for acquired chemotherapy resistance in neuroblastoma
Auditori J. Plaza · Hospital Sant Joan de Déu Barcelona